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Abstract

Author Manuscript

Neuroimaging of cerebral glucose metabolism and blood flow is ideally suited to assay widelydistributed brain circuits as a result of local molecular events and behavioral modulation in the
central nervous system. With the progress in novel analytical methodology, this endeavor has
succeeded in unraveling the mechanisms underlying a wide spectrum of neurodegenerative
diseases. In particular, statistical brain mapping studies have made significant strides in describing
the pathophysiology of Parkinson’s disease (PD) and related disorders by providing signature
biomarkers to determine the systemic abnormalities in brain function and evaluate disease
progression, therapeutic responses, and clinical correlates in patients. In this article, we review the
relevant clinical applications in patients in relation to healthy volunteers with a focus on the
generation of unique spatial covariance patterns associated with the motor and cognitive
symptoms underlying PD. These characteristic biomarkers can be potentially used not only to
improve patient recruitment but also to predict outcomes in clinical trials.
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Introduction

Author Manuscript

Functional brain imaging with positron emission tomography (PET) and single-photon
emission computed tomography (SPECT) has provided novel insights into the
pathophysiology of Parkinson’s disease (PD) and related movement disorders. The integrity
of the presynaptic nigrostriatal dopaminergic systems can be evaluated by measuring the
dopamine storage capacity using [18F] fluorodopa (FDOPA), or dopamine transporter
(DAT) binding using radiotracers such as [123I]βCIT and [18F]FPCIT (see reviews [1, 2]).
Postsynaptic dopamine receptor systems can be assayed with radioligands that bind
specifically to D1 or D2 receptors. In addition, PET has been used to study regional neuronal
activity by quantifying resting-state regional cerebral glucose metabolism (rCMRglc) with
[18F]fluorodeoxyglucose (FDG)[3] and regional cerebral blood flow (rCBF) activation
responses with [15O]H2O[4]. Abnormal rCBF distributions in the resting state can also be
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measured using PET and SPECT perfusion tracers. In particular, imaging of cerebral
metabolism and blood flow has contributed greatly to the understanding of the abnormal
brain circuitry underlying the pathophysiology of PD.

Author Manuscript

PET/SPECT can be particularly useful in assessing the consequences of nigrostriatal
dopamine deficiency on the functional networks of the basal ganglia. Although the primary
pathological abnormality in PD is located in the substantia nigra, the degeneration of
dopaminergic projection neurons to the striatum leads to widespread changes in the
functional activity of the basal ganglia[5]. Specifically, the loss of inhibitory dopaminergic
input to the striatum increases the inhibitory output from the putamen to the external globus
pallidus (GPe), decreases the inhibitory output from the GPe to the subthalamic nucleus
(STN), and causes functional over-activity of the STN and internal globus pallidus (GPi),
resulting in reduced output from the ventrolateral thalamus to the cortex. This classic model
has been modified to emphasize the cognitive dysfunction associated with PD[6] and is
linked to concurrent changes in regional glucose metabolism and blood flow.

Author Manuscript

We review the advances in functional brain imaging studies of PD in the resting state based
on analyses of rCMRglc and rCBF in patients and healthy volunteers. As in most
neurodegenerative conditions, these two variables are considered to be coupled in PD and
related to synaptic activity at the regional level. We also summarize the use of novel
analytical techniques in the clinical diagnosis and evaluation of PD. These include both
univariate and multivariate statistical approaches such as statistical parametric mapping
(SPM) and principal component analysis (PCA) for volume of interest (VOI) or voxel-wise
analysis over the whole brain. In addition, we focus on the application of these imaging
methods to the selection of suitable candidates for surgical trials and the assessment of their
treatment outcome.

Functional Brain Imaging: Univariate Analyses

Author Manuscript

PET/SPECT imaging of rCMRglc and rCBF has been used extensively to identify changes
in regional brain function in patients with PD comparable to those revealed in experimental
animal models[7, 8]. The bulk of this effort is based on the use of SPM to localize regionally
specific differences and functional-clinical correlates in PD patients scanned when they are
off dopaminergic medications. Functional brain images are spatially transformed into a
standard anatomical space to allow mapping analysis on a voxel basis. To reduce interindividual variability in anatomical and functional substrates, images are usually rationormalized to a global mean or other reference value that is assumed to be preserved in the
diseased brain. Consequently, only relative measures of functional brain activity are used in
most studies.
Cerebral Metabolism Studies
Because the local rate of glucose metabolism is a direct marker of synaptic activity, PET
with FDG has been the most common approach to studying abnormal brain function in PD.
By using FDG PET images from multiple cohorts of patients and healthy controls we and
other researchers have reported a reproducible pattern of abnormal regional metabolism in
PD (Fig. 1) characterized bilaterally by increases in the putamen, thalamus, cerebellum,
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pons, and sensorimotor cortex (SMC), and decreases in the lateral frontal and parietooccipital areas[9–11]. This is in accordance with a dual-tracer PET study with both FDG and
[15O]O2 showing bilaterally increased energy metabolism in the putamen and pallidum in
early unmedicated PD patients[12]. Regional metabolism in the cerebellum is also elevated in
early-stage and advanced PD patients[13, 14], suggesting that cerebellar hypermetabolic
activity in PD is closely linked to akinesia and rigidity but not to tremor. It has been further
reported that clinical scores of motor symptoms are correlated positively with rCMRglc in
the bilateral putamen and pallidum[15], and in the midbrain, cerebellum, and motor
cortex[16]. These reports indicate a pathophysiologic association between subcortical
hypermetabolism and motor dysfunction in PD.

Author Manuscript
Author Manuscript

Unique features of cortical hypometabolism in PD have also been frequently reported. An
early study reported pronounced occipital hypometabolism in the more severely affected
hemisphere in PD[17]. The asymmetry in this metabolic reduction correlated inversely with
finger-tapping performance in a subset of patients with more unilateral motor impairment.
While hypometabolism is limited in the frontal and occipital cortices of PD patients with no
cognitive impairment[18], it becomes more widespread within cortical regions in advanced
PD[14]. Further, the relationships of abnormal rCMRglc with clinical symptoms and
impaired striatal DAT binding have been examined in de novo untreated PD patients[19].
Correlation analyses showed that the UPDRS motor ratings were negatively correlated with
rCMRglc in the premotor cortex (PMC), while putaminal DAT binding was positively
correlated with rCMRglc in the premotor, dorsolateral prefrontal, anterior prefrontal, and
orbitofrontal cortices. This method also led to a set of disease-related brain templates for PD
and atypical PD to aid single-case differential diagnosis[10, 11]. These results may represent
the cortical functional correlates of nigrostriatal dysfunction in the motor basal gangliacortical circuitry in parkinsonism.

Author Manuscript

FDG PET has also been used to delineate the metabolic functional correlates of PD with
cognitive impairment. Regional metabolism is markedly reduced in the inferior/superior
parietal and occipital cortices in PD patients with autonomic failure[20], in agreement with
the negative correlation reported between intellectual impairment in PD and rCMRglc in
posterior association regions such as the bilateral parietal and occipital gyri[21]. Both studies
provided early indications that cortical hypometabolism may be primarily associated with
cognitive dysfunction in PD. It was also found that the relative metabolic activity in
typically affected cortical regions was significantly correlated with scores for cognition, but
not with those for motor performance and behavior in a combined cohort of PD patients
without and with dementia[22]. This measure gave a high sensitivity and specificity of 0.91
and 1.00 for an ultimate clinical diagnosis of dementia. Indeed, we found that worsening
executive dysfunction in non-demented PD patients is related bilaterally with lower
rCMRglc in parieto-occipital association regions, and with higher rCMRglc in the
cerebellum (Fig. 2). Extensive areas of hypometabolism are also evident in the posterior
cortical regions, including the temporo-parieto-occipital, medial parietal, and inferior
temporal cortices in PD patients with mild cognitive impairment[18]. These results support
the notion that posterior cortical dysfunction is the primary imaging feature of cognitivelyimpaired PD patients at risk for developing dementia.
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Owing to the short half-life of the radiotracer, H2O PET has been primarily used in brain
activation studies to examine physiological processes underlying motor execution and
learning[23, 24]. Nevertheless, this method has also been used to map rCBF alterations in PD
patients at rest. Both rCBF and rCMRglc data measured with PET yield similar patterns of
subcortical hyperactivity and cortical hypoactivity in PD patients; these are highly
comparable to those from resting-state rCBF studies using SPECT perfusion data. For
example, one study compared parametric maps of globally normalized rCBF in PD patients
and age-matched normal volunteers using SPECT with 99mTc-ethyl cysteinate dimer
(ECD)[25]. In patients with early-stage PD, rCBF increased in the bilateral putamen and the
right hippocampus relative to controls. In patients with late-stage PD, rCBF increased in the
bilateral putamen, pallidum, hippocampus, and cerebellum, the left ventrolateral thalamus,
and the right insula and inferior temporal cortex. Thus, significant rCBF changes in PD are
associated with the pathophysiology and progression in the functional architecture of
thalamocortico-basal ganglia circuits and related pathways.

Author Manuscript

By contrast, rCBF declines in the supplementary motor area (SMA) and the dorsolateral
prefrontal cortex (DLPFC) in PD patients using SPECT with 99mTc-hexamethyl propylene
amine oxime (HMPAO)[26]. In a subgroup of patients with Hoehn-Yahr III/IV, rCBF
decreased in the SMA, and in the DLPFC and insular cortex. The degree of rCBF decline in
the DLPFC or the insular cortex was correlated with UPDRS motor scores. rCBF was also
significantly reduced in the bilateral posterior parietal and occipital cortices in nondemented PD patients relative to normal individuals using SPECT with N-isopropyl-p[123I]iodoamphetamine (IMP)[27]. There was a strong positive correlation between the
scores in a visual-processing task and rCBF in the right visual association area in PD
patients. This work demonstrates that posterior parietal and occipital hypoperfusion is a
consistent feature in non-demented PD patients and the latter is likely to underlie impaired
visual cognition.
SPECT perfusion data have proven useful for characterizing the unique features of cortical
hypoperfusion in PD with dementia. Previous studies in patients with Hoehn-Yahr III–IV
PD showed significant rCBF decreases in the left frontal/parietal association cortices with
IMP[28] and in the precuneus and inferior parietal regions with HMPAO[29], consistent with
the impaired visuospatial perception in demented PD. Furthermore, temporal and more
extensive parietal hypoperfusion are often seen in demented patients[30]. The cortical
hypoperfusion might be clinically useful in discriminating PD patients with dementia from
those without cognitive impairment.

Author Manuscript

In summary, imaging studies of brain metabolism and perfusion have revealed unique and
comparable pathological features underlying varying degrees of motor and cognitive
dysfunction in patients with PD. The characteristic patterns of abnormal regional cerebral
metabolism and perfusion are to a large degree independent of global measures of brain
activity in non-demented patients with PD as described previously[3, 31]. The generally
similar findings from these two imaging measures of brain function indicate close coupling
between cerebral blood flow and metabolism in PD under resting conditions. These results
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have established molecular-functional-clinical correlates of the impaired cortico-subcortical
circuitry in PD.

Functional Brain Imaging: Multivariate Analyses
The measurements of local metabolic rates or blood flow changes may not fully account for
the complex nature of brain networks involved in neurodegenerative processes and their
modulation by therapy. These processes may be better represented by spatial covariance
patterns among spatially distributed functional regions that can be altered by the presence of
disease or behavioral activation. Many computing methods have been used in the analysis of
rCMRglc and rCBF data to compare groups in the same resting state[32–35] and under brain
activation conditions[36–38]. The resultant topographic patterns describe functional
connectivity and are commonly referred to as disease-specific brain networks.

Author Manuscript

Metabolic Network Analyses
We have developed a statistical modeling approach to detect and quantify regional
functional interactions in neurodegenerative disorders[31, 39]. This method, known originally
as the scaled subprofile model (SSM), uses PCA to identify regional covariance patterns
using images from a combined group of patients and controls or a single group of
individuals (software freely available at our website http://www.feinsteinneuroscience.org).
These patterns reflect the covariation of increased or decreased activity in regional brain
function in patients relative to the normal population or in relation to the correlation with a
behavioral variable.

Author Manuscript

SSMPCA allows for the prospective quantification of covariance pattern expression in
individual subjects. Subject scores computed from functional brain images can be correlated
with clinical or physiological parameters on a single-case basis[3]. Of note, these scores have
higher signal-to-noise ratios than decreasing levels of dopaminergic markers such as
FDOPA or FPCIT with increasing disease severity. Thus, SSMPCA may offer greater
sensitivity for detecting spatiotemporal changes in brain network activity during progression
or following therapy.

Author Manuscript

Many imaging studies have been performed to implement and validate network methods for
the diagnosis and evaluation of patients with PD and related movement disorders[39, 40].
Using SSMPCA analysis of FDG PET data we consistently revealed a pattern of regional
metabolic covariation characterized by lentiform, thalamic, cerebellar, pontine, and
sensorimotor hypermetabolism, along with hypometabolism in the lateral PMC, SMA, and
parieto-occipital regions (Fig. 3). The subject scores for this PD-related covariance pattern
(PDRP) are elevated in PD patients, and are correlated positively with clinical disease
ratings and negatively with striatal FDOPA uptake or DAT binding[3, 41, 42]. This pattern has
been confirmed in multiple cohorts of PD patients[43–45] and parkinsonian primates[46]
scanned with different tomographs. In addition, PDRP expression showed an excellent testretest reproducibility [intraclass correlation coefficient (ICC) >0.94] between FDG PET
imaging sessions conducted OFF and ON medications in independent groups of PD patients
at early and advanced stages[39]. Moreover, disease-specific covariance patterns for multiple
system atrophy (MSA), progressive supranuclear palsy and parkinsonian tremor have also
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been developed for more accurate differential diagnosis of PD from atypical parkinsonism
on a single-case basis[45, 47–49].

Author Manuscript

SSMPCA analysis of FDG PET data can also reveal the specific networks associated with
cognitive dysfunction in PD. By using this method in non-demented PD patients, we
identified a covariance pattern that is correlated with memory and executive functioning[50].
This PD-related cognitive pattern (PDCP) is characterized by hypermetabolism in the
cerebellar vermis and dentate nuclei and hypometabolism in frontal and parietal association
areas (Fig. 4). Similar results have been reported from VOI-based SSMPCA analysis[51] and
another multivariate method based on partial least squares[34]. PDCP activity predicted
memory or visuospatial function, and perceptual motor speed in a prospective validation
sample of PD patients of similar disease duration and severity. In addition, PDCP scores
showed excellent test–retest reliability (ICC >0.89) in patients undergoing repeat FDG PET
imaging OFF and ON medications. PDCP is orthogonal to PDRP as its expression is
independent of UPDRS motor scores in individual PD patients.

Author Manuscript

Importantly, the topography of the PD-related metabolic covariance pattern identified in
these studies is in line with experimental models of parkinsonism[3, 46]. Specifically, this
supports the notion of enhanced pallido-thalamic inhibition as the main functional substrate
of parkinsonian bradykinesia. The subject scores for PDRP correlate with objective disease
severity ratings and with independent measures of nigrostriatal dopamine function.
Furthermore, the PDRP scores and rCMRglc within key hypermetabolic regions obtained
from preoperative FDG PET scans are related to neuronal firing rates in the GPi and STN
measured during stereotaxic neurosurgery[52, 53]. On the contrary, the PDCP scores did not
show such relationships despite their correlation with cognitive impairment in patients. This
is further evidence that the PDRP is an indirect measure of an abnormal physiological signal
resulting from hyperactivity in the basal ganglia-thalamic-motor cortical loop.
Blood Flow Network Analyses
PD-related brain network patterns based on SSMPCA can be directly identified and
prospectively accessed by using rCBF images from PET or SPECT. VOI-based network
analysis of ECD SPECT data from PD patients and age-matched healthy controls revealed a
pattern characterized by relative increases in putaminal, thalamic, and cerebellar perfusion
along with decreases in the frontal operculum and in the medial temporal cortex[54]. The
subject scores for this PDRP pattern were significantly increased in PD patients relative to
healthy control and MSA groups. These features agree very well with those reported in the
PDRP derived from FDG PET images.

Author Manuscript

Notably, the PET-derived PDRP scores computed from ECD SPECT scans more accurately
separate PD patients from normal controls and MSA patients[54, 55]. Receiver operating
characteristic analysis indicated that the PDRP measures yielded an overall diagnostic
accuracy of 0.91, with a sensitivity of 0.97 and specificity of 0.71 and 0.80 for
distinguishing PD from the other two groups. Hence, the disease-related patterns identified
with FDG PET can be reliably assessed in SPECT perfusion scans to discriminate between
healthy controls and patients with PD and atypical parkinsonism.
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The disease-related patterns seen in PDRP derived from FDG PET and ECD SPECT images
are also similar to those revealed by another multivariate brain mapping method based on
independent component analysis (ICA). A SPECT study compared differences in rCBF
between PD patients and age-matched controls with SPM after decomposing the images into
disease-related and unrelated components[33]. In the disease-related components, PD
patients revealed significantly higher normalized rCBF in the putamen, pallidum, thalamus,
brainstem, and cerebellum, and significant hypoperfusion in the parieto-temporo-occipital
cortex, DLPFC, insula, and cingulate gyrus. Importantly, motor UPDRS scores in patients
correlated negatively with rCBF in the insula and cingulate gyrus. The abnormal regions
revealed by both ICA and PCA are consistent with the current model of parkinsonism.

Author Manuscript

We have validated the PDRP or PDCP network as a reliable measure of parkinsonism or
cognitive dysfunction by computing its activity prospectively in H2O and FDG PET scans
from PD patients and healthy volunteers[56]. PDRP expression was significantly elevated in
PD patients, using either H2O or FDG PET scans. A significant correlation was present
between PDRP/PDCP scores computed from H2O and FDG images in the same cohort of
PD patients. This relationship has established the clinical utility of network quantification
with rCBF data in the early differential diagnosis of PD. For example, PDRP/PDCP scores
were computed in a prospective cohort of normal controls and patients with early- and latestage PD who underwent H2O PET imaging. We found that PDRP scores performed better
than those for PDCP in separating early PD from controls. This difference in PDRP and
PDCP scores from cross-sectional data is in line with the observation from a longitudinal
study of disease progression with FDG PET[42], indicating that the manifestation of motor
symptoms precedes cognitive dysfunction in early PD.

Author Manuscript

The reliability of PDRP/PDCP expression computed in rCBF scans has also been evaluated
within subjects using a test–retest design in mild and advanced PD patients[56]. These
patients were scanned twice within one H2O PET imaging session at baseline and during
treatment with levodopa (LD) infusion or deep brain stimulation (DBS). PDRP/PDCP scores
measured with rCBF data have very high reproducibility (ICC >0.92), comparable to that
from rCMRglc data acquired between FDG PET sessions separated by up to 2 months. This
high reproducibility is evident in both early-stage and advanced PD patients scanned at
baseline and during treatment.

Author Manuscript

PDRP/PDCP expression can also be assessed prospectively with rCBF data acquired from
arterial spin labeling (ASL) perfusion MRI. We have shown that ASL MRI is comparable to
FDG PET in quantifying PDRP network activity in individual patients and healthy
controls[57]. Indeed, the PDRP scores in PD patients measured concurrently with both rCBF
and rCMRglc images were equally elevated from the controls and significantly correlated
with each other. With further technical refinement this imaging modality has been successful
in deriving analogous spatial covariance patterns associated with motor and cognitive
dysfunction in PD[58].
In summary, the motor and cognitive symptoms of PD have been linked to abnormal spatial
covariance patterns involving different aspects of the basal ganglia-thalamocortical
pathways. These patterns closely resemble specific physiological and anatomical brain
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networks known to be operating in disease states, and are highly reproducible across
independent patient populations and tomographs at separate institutions. Individual subject
scores for the motor-related topography are significantly elevated in PD patients and
correlate with bradykinesia and rigidity ratings. In addition, subject scores for the cognitionrelated topography predict behavioral performance. Besides the use of FDG PET data,
pattern derivation and prospective assessment can also be achieved with rCBF data obtained
from PET and more routine SPECT methods as well as newly-developed MRI perfusion
techniques.

Functional Neuroimaging in the Evaluation of Therapeutic Interventions

Author Manuscript

Reliable in vivo markers of neuronal activity are necessary to assess the medical or surgical
outcome in PD. Currently available clinical rating scales are inherently variable and
relatively insensitive, and may not accurately reflect the extent of therapy-mediated changes
in regional brain function. Conversely, quantitative functional imaging markers of cerebral
metabolism and blood flow in the resting state may serve as suitable outcome measures for
the treatment of PD. These measures may help select patients for clinical trials by providing
more accurate diagnosis on an individual case basis and may afford a useful tool in
predicting clinical outcomes for certain neurosurgical interventions.
Effects of Dopaminergic Therapy on Brain Function

Author Manuscript

PET/SPECT has been used to quantify regional functional changes associated with
successful drug therapy. We reported that LD infusion significantly decreased rCMRglc in
the putamen, thalamus, cerebellum, and primary motor cortex, along with a significant
decline in PDRP expression[59] (Fig. 5). Changes in pallidal metabolism and PDRP activity
were negatively correlated with clinical improvement in UPDRS motor ratings. These
confirmed that lentiform hypermetabolism or hyperfusion in PD may be in part reversible by
LD[60]. The response to dopaminergic therapy in PD patients may be mediated by the
modulation of cortico-striato-pallido-thalamocortical pathways.

Author Manuscript

PET has played a key role in unraveling the metabolic and neurovascular effects of LD
therapy for PD. Both H2O and FDG PET images have been used to quantify LD-mediated
changes in the expression of motor- and cognition-related PD covariance patterns as well as
in rCBF and rCMRglc in PD patients before and after intravenous LD infusion[61]. There
was a significant dissociation between rCBF and rCMRglc in the modulation of the PDRP
by LD treatment, characterized by decreases in network activity in the rCMRglc images but
concurrent increases in the rCBF images. This treatment also induced decreases in rCMRglc
and increases in rCBF in the putamen/pallidum, dorsal midbrain/pons, STN, and ventral
thalamus. These are the same regions that exhibit increased brain activity in PD with either
rCMRglc or rCBF data obtained off medication as described above. These results indicate
that flow–metabolism dissociation is a unique feature of LD treatment. The elevations in
rCBF and in the corresponding PDRP network activity may be attributed to a direct action of
dopaminergic drugs on the microvasculature in the close proximity of monoaminergic
terminals. This LD-mediated disassociation between blood flow and metabolism calls for
great caution when interpreting rCBF findings in patients who have taken dopaminergic
medications or undergone insufficient washout before imaging.
Neurosci Bull. Author manuscript; available in PMC 2015 September 01.
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Neurosurgery can provide effective symptomatic relief in patients with advanced PD by
performing localized interventions on several deep nuclei that serve as key relay stations
within the basal-ganglia-cortical motor circuitry and related pathways. DBS at high
frequency offers a reversible treatment for PD without the permanent side-effects caused by
an ablative lesion. In addition, DBS parameters can be adjusted postoperatively for optimal
clinical benefits on an individual basis. A number of subcortical targets have been
stimulated to achieve long-term improvement in the motor and non-motor symptoms of
PD[62–64], including mainly pallidal and subthalamic DBS to improve general motor features
and ventral intermediate (Vim) thalamic DBS to suppress tremor.

Author Manuscript

Neuroimaging studies with rCMRglc and rCBF have shed important light on the therapeutic
mechanisms underlying these procedures. Ipsilateral and contralateral changes in regional
brain function can be detected in the PMC, SMC, SMA, and cerebellum using both FDG
and H2O PET following unilateral DBS at the internal and external parts of the globus
pallidus[9, 65]. Interestingly, unilateral Vim DBS leads to rCBF decreases in the ipsilateral
SMC and the contralateral cerebellum, as well as concurrent increases in the ipsilateral
ventral thalamus[66]. Changes in tremor acceleration and rCBF are correlated in the
ipsilateral cortical regions; changes in tremor frequency and rCBF are correlated in the
contralateral cerebellum and pons. These results suggest that DBS delivers symptomatic
relief by modulating the activity of cerebello-thalamocortical pathways.

Author Manuscript

Stimulation at the STN is considered to be more effective than at the GPi in improving PD
symptoms by affecting more than one inhibitory output area of the basal ganglia, i.e. both
the GPi and the substantia nigra pars reticulata. An FDG PET study showed that rCMRglc
decreased in the left rostral cerebellum with STN-DBS, but increased in both lower thalami
extending to the midbrain area and remotely in the right frontal, temporal, and parietal
cortices[14]. These data demonstrate an activating effect of DBS on its target structures and
suggest a central role of the STN in motor, association, limbic, and cerebellar-basal ganglia
circuits.

Author Manuscript

FDG PET has proven to be useful for directly comparing the specific metabolic effects of
different interventions. It has been reported that metabolism is reduced in the GPi and caudal
midbrain but elevated in the posterior parietal region following STN stimulation and
subthalamotomy[16]. While the metabolic decline in the GPi is greater with a lesion, the
metabolic increase is greater with stimulation. PDRP expression is similarly reduced with
both treatments. Moreover, we reported that both STN stimulation and LD therapy result in
significant metabolic reductions in the putamen/pallidum, SMC, and cerebellar vermis, as
well as elevations in the precuneus[67]. Reduction in the lentiform metabolism may reflect
deactivation of the inhibitory basal ganglia output nuclei following suppression of the
synaptic activity of STN projections. Comparable declines in PDRP activity have also been
observed with both interventions (Fig. 5), and they are correlated with clinical improvement.
This is in excellent agreement with the findings reported with FDG PET in
subthalamotomy[68] and DBS at the GPi[9] and STN[69]. These results suggest that effective
treatments for PD are facilitated by a common mechanism involving the modulation of
pathological brain networks.
Neurosci Bull. Author manuscript; available in PMC 2015 September 01.
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It is of interest to note that PDCP expression assessed by rCMRglc and rCBF scans in the
same patients was not changed by symptomatic therapy with either intravenous LD infusion
or STN-DBS[61]. Hence, PDCP assessment did not reveal any flow-metabolism
disassociation evident with LD administration in PDRP noted above. These findings support
the hypothesis that PDCP network activity is a reproducible imaging biomarker of cognitive
function in PD and this measure may prove useful in clinical trials targeting the non-motor
symptoms of PD.

Author Manuscript

H2O PET has been used to measure resting rCBF responses to STN-DBS. Cerebral blood
flow increases in the thalamus and midbrain, but declines bilaterally in premotor cortex[70].
Of note, significant correlations are present between improved rigidity and decreased rCBF
in the SMA, between improved bradykinesia and increased rCBF in the thalamus, and
between improved postural reflexes and decreased rCBF in the pedunculopontine nucleus
(PPN). Increased rCBF in the thalamus and midbrain agrees with the rCMRglc results from
FDG PET[14, 67]. These data indicate that STN stimulation appears to increase the firing of
STN output neurons, which enhances inhibition of the thalamocortical projections,
ultimately decreasing blood flow in cortical targets. Furthermore, blood flow increases
bilaterally in the STN and in the left lentiform during bilateral STN DBS[71], but declines in
the left SMA (BA 6), left ventrolateral thalamus, and right cerebellum. Changes in rCBF in
the basal ganglia or the SMA and thalamus are both correlated with the improvement in
motor function. STN DBS in resting patients may also result in deactivation of the thalamic
anteroventral and ventrolateral nuclei and the SMA.

Author Manuscript

STN-DBS in PD has also been examined by measuring resting-state rCBF with SPECT. In
patients with stable clinical improvement during a long-term follow-up study[72], STN-DBS
at 5 months induced a reversible increase of rCBF in the pre-SMA, PMC, and DLPFC
regions from the preoperative baseline. Blood flow increased further from 5 to 42 months in
these frontal areas, and also in the primary sensorimotor cortices, pallidum, ventral lateral
thalamus, cerebellum, pons, and midbrain, involving the substantia nigra. The improvement
in motor scores was correlated with the rCBF increase in the pre-SMA and PMC. Long-term
STN-DBS leads to progressive improvement in neural activity in the frontal motor/
association areas, along with increased activity in subcortical structures in the later phase.

Author Manuscript

There are bound to be agreements and discrepancies across the many neuroimaging studies
on the functional effects of STN-DBS. The major disagreement is likely to come from
different neurosurgical protocols, imaging techniques, and analytical methods. The second
difference may stem from varied and limited sample sizes, and the inhomogeneous clinical
characteristics of PD patients included in the study. The third difference may be the use of
rCBF or rCMRglc as an outcome measure for the therapeutic trial. Although STN
stimulation results in similar changes in regional brain activity and PDRP expression
whether in rCMRglc or rCBF scans, a small difference may still arise from the potential
residual effects of dopaminergic medications on rCBF values across studies.
H2O PET can also detect the rCBF activation patterns induced by STN-DBS under task
conditions. One study disclosed that rCBF increases significantly in the SMA, cingulate
cortex, and DLPFC with STN stimulation during a motor activation task[73]. This suggests
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that STN DBS plays a role in enhancing non-primary motor cortical areas, especially the
DLPFC showing greater activation than in the GPi during effective stimulation. Bilateral
STN DBS worsened the performance of a fast-paced cognitive task of random number
generation in PD[74]. Cerebral blood flow was reduced in the left dorsal and inferior frontal
gyri, DLPFC, and the posterior and right anterior cingulate, but increased in the right GPi
during the task. STN stimulation activates its output neurons to the GPi and significantly
changes pallidal coupling with prefrontal, cingulate, and temporal cortices during the
performance of a cognitive experiment.

Author Manuscript

It has been proposed that the axial symptoms in PD can be effectively improved by
stimulation at the PPN. Cerebral blood flow was measured by H2O PET at rest and during a
self-paced motor task of the lower limbs in patients with advanced PD who were treated
with unilateral PPN-DBS[75]. Stimulation induced significantly increased rCBF in
subcortical regions such as the thalamus, cerebellum, and midbrain as well as in different
cortical areas involving the medial SMC extending into the caudal SMA (BA 4/6). Some of
these regions are similar to the H2O PET observations during STN-DBS. An FDG PET
study also demonstrated that PPN DBS can improve non-motor function in the cognitive
domain as indicated by relative prefrontal and cingulate hypermetabolism and cerebellar
hypometabolism[76]. It remains to be seen in a large sample how PPN-DBS affects the
clinical correlates of regional brain function and whether it can modulate PDRP activity as
evident in other interventions.

Author Manuscript

In summary, PET/SPECT imaging of rCMRglc and rCBF is a useful experimental method
for assessing the modulation of structure/functional relationships during the successful
treatment of PD. Treatment with LD or DBS surgery in patients with PD alters activity in
the putamen, pallidum, thalamus, and cerebellum, and partly restores the physiological
substrate in limbic and associative cortical regions of the basal ganglia. In addition, clinical
improvement is correlated with the changes in regional brain activity as well as in the
expression of a PD-related covariance pattern. These interventions are consistently
associated with modulation of regional brain function and suppression of a specific
functional network involving elements of the cortico-striato-pallido-thalamocortical and the
cerebello-cortical motor loops.

Conclusion

Author Manuscript

PET/SPECT has been widely used to identify changes in regional cerebral glucose
metabolism and blood flow in PD. The measurements of cerebral metabolism and perfusion
provide unique information on the topography of widespread functional alterations in the
brains of PD patients, which is not available from studies with presynaptic or postsynaptic
dopaminergic radioligands. Much effort has been devoted to the development of novel
analytical methods for the validation of brain networks in functional imaging data. Such
spatial covariance patterns may afford clinically useful markers in the differential diagnosis
of parkinsonism and in the evaluation of disease severity and therapeutic response. Many
studies have established the specific roles of imaging in preoperative patient selection for
clinical trials in parkinsonism. A major contribution in this line of research has been a
complementary analytical approach using both voxel-wise brain mapping and network

Neurosci Bull. Author manuscript; available in PMC 2015 September 01.

Peng et al.

Page 12

Author Manuscript

modeling strategies to determine the relationships between localized functional abnormality
and the expression of widely distributed brain networks. Applications of these techniques
may provide greater insights into the pathophysiology of PD and offer more accurate
assessment of the inherent functional changes that occur with disease onset, progression, and
successful therapy.
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Fig. 1.

A: Brain regions with significant metabolic abnormality identified by SPM analysis of
resting-state FDG PET scans in patients with Parkinson’s disease (PD) and age-matched
normal volunteers. PD patients showed relative metabolic increases (red) in the putamen/
globus pallidus (GP) and thalamus, in the cerebellum and pons, and in the sensorimotor
cortex (SMC), along with metabolic decreases (blue) in the parieto-occipital association
areas. B: Bar diagrams (mean ± standard error) illustrating increased metabolic activity in
the subcortical area and decreased activity in the cortex using rCMRglc data (P <0.01) that
compared the PD patients to the controls. (Produced by the authors using FDG PET images
described by Ma et al. J Cereb Blood Flow Metab 2007[39]. The display shows t-maps that
are significant at P <0.001. The regional brain activity values were obtained post-hoc with a
spherical VOI 8 mm in diameter centered at the peak of significant SPM clusters.)

Author Manuscript
Author Manuscript
Neurosci Bull. Author manuscript; available in PMC 2015 September 01.

Peng et al.

Page 18

Author Manuscript
Author Manuscript

Fig. 2.
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A: Brain regions with significant behavioral correlations identified by SPM regression
analysis of resting-state FDG PET scans in non-demented patients with Parkinson’s disease
(PD). Scores on the California verbal learning test (CVLT) were positively correlated with
metabolic activity in the precuneus and bilateral parieto-occipital association areas (red), and
negatively with metabolic activity in the right brainstem and bilateral cerebellum (blue). B:
Scatter plots illustrating significant linear relationships between the measure of cognitive
dysfunction in PD with decreased brain activity in the parieto-occipital regions and
increased brain activity in the cerebellum with rCMRglc data. Note that a lower CVLT score
indicated a higher degree of cognitive dysfunction in individual patients. (Produced by the
authors using FDG PET and clinical data described by Huang et al. NeuroImage 2007[50].
The display represents t-maps that are significant at P <0.01. The regional metabolic values
were obtained post-hoc with a spherical VOI 8 mm in diameter centered at the peak of
significant SPM clusters.)
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Fig. 3.
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A: Parkinson’s disease-related pattern (PDRP) identified by SSMPCA spatial covariance
analysis of resting-state FDG PET scans in patients with Parkinson’s disease (PD) and agematched normal volunteers. This pattern was characterized by relatively increased metabolic
activity (yellow) in the putamen/globus pallidus (GP) and thalamus, in the cerebellum and
pons, and in the SMC. These changes covaried with relatively decreased metabolic activity
(blue) in the lateral premotor cortex (PMC) and in the parieto-occipital association regions.
B: Scatter plots of individual values and mean (± standard deviation) for PDRP expression
in healthy controls (open circles) and PD patients (filled circles). PDRP network scores were
significantly elevated in patients relative to controls. A higher PDRP score corresponded
with more severe motor symptoms in individual patients. [Reproduced by the authors using
FDG PET images described by Ma et al. J Cereb Blood Flow Metab 2007[39]. The display
represents voxels that contributed significantly to the network at P≤0.001, and were
demonstrated to be reliable (P <0.001) on bootstrap estimation.]
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Fig. 4.

Author Manuscript

A: Parkinson’s disease-related cognitive pattern (PDCP) identified by SSMPCA spatial
covariance analysis of resting-state FDG PET scans in non-demented PD patients. This
pattern was characterized by covarying metabolic reductions (blue) in the rostral
supplementary motor area (pre-SMA) and precuneus, as well as in the dorsal premotor
(PMC) and posterior parietal regions, and in the left prefrontal cortex. Relative metabolic
increases (yellow) in the cerebellar vermis and dentate nuclei (DN) were also evident as part
of this topography. B: Brain-behavioral correlations between PDCP network expression and
neuropsychological performance in non-demented PD patients. There was a significant
linear relationship between PDCP network activity and scores in the California verbal
learning test (CVLT). Note that a lower CVLT score and higher PDCP activity indicated a
greater degree of cognitive dysfunction in individual patients. (Reproduced by the authors
using FDG PET and clinical data described by Huang et al. NeuroImage 2007[50].) The
display represents regions that contributed significantly to the network at P≤0.01 and were
demonstrated to be reliable (P <0.05) by bootstrap estimation.
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Network modulation and clinical correlation with antiparkinsonian interventions in patients
assessed with FDG PET. A: Bar graph (mean ± SE) illustrating relative changes in the
expression of the PD-related metabolic covariance pattern (PDRP) during antiparkinsonian
therapy with LD infusion (shaded bar) and ventral pallidotomy, pallidal and STN DBS, and
subthalamotomy (filled bars). Reduction in PDRP activity was greater in lesion versus DBS
at the same target or in STN versus GPi by either lesion or DBS. For unilateral surgical
intervention, PDRP reflected changes in network activity in the operated hemisphere. With
LD infusion, the PDRP changes were averaged across hemispheres. CN, Control. B:
Correlations between clinical improvement in UPDRS motor rating and treatment-mediated
changes in PDRP activity. The clinical outcome in individual patients was significantly
correlated with the degree of PDRP suppression following levodopa administration in mild
PD patients and STN DBS in advanced PD patients. (Reproduced by the authors using FDG
PET and clinical data described by Feigin et al. Neurology 2001[59] and Asanuma et al.
Brain 2006[67]. *P <0.01; **P <0.005 vs untreated condition)
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